Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of algae biofuel maker Solazyme
So what: Raymond James analyst Pavel Molkhanov downgraded the stock from outperform to market perform citing the stock's recent run-up as the cause. He had a $14 price target previously and said that now that the stock has hit the target, the risk-reward is no longer attractive.
Now what: At The Motley Fool, we don't take analyst upgrades or downgrades too seriously, and this short-term move shouldn't affect long-term investors' theses. I haven't liked Solazyme for a more fundamental reason: We have yet to see alternative fuels or other products become a sustainable, long-term business. It just isn't a risk I would be willing to take right now given the low cost of natural gas, a more well understood alternative fuel source than algae.
Interested in more info on Solazyme? Add it to your watchlist by clicking here.
